Posts Tagged ‘biosimilars’
Biosimilars &“Pay-for-delay” Settlements
By: Samantha Schram Competition in the pharmaceutical industry is fostered by the regulatory frameworks enacted to achieve a balance between innovation and consumer interests. In 1984, Congress enacted the Hatch-Waxman Act in an effort to address the growing cost of health care, as well as the necessity of continued medical innovation.[2] The Hatch-Waxman Act…
Read More